Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of vemurafenib in BRAF V600-positive radioactive iodine–resistant papillary thyroid cancer
2010-024133-23Phase 2Completed
- Sponsor
- Roche
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vemurafenib in papillary thyroid cancer (PTC), sponsored by Roche. Primary endpoint: Best overall response rate (BORR). Started May 2011; status: completed.
02
Drugs
vemurafenib
03
Conditions
papillary thyroid cancer (PTC)
Beyond the preview
Go deeper on 2010-024133-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024133-23.